In a report published Thursday, Morgan Stanley analyst David Risinger resumed coverage on Endo International plc - Ordinary Shares ENDP with an Overweight rating and $101.00 price target.
In the report, Morgan Stanley noted, "We believe investors under-appreciate the durability of Endo's long-term growth prospects; $101 PT explained. We model 2015-2020E (5-yr CAGR) rev growth of 6% and EPS growth of 15%. Our $101 target represents 20x '16E EPS of $5.03, assuming a PEG ratio of 1.3x EPS growth of 15%. Auxilium deal enhances high-value branded pharma business. The Auxilium merger closed on 1/29/15. We estimate Auxilium will boost Endo's 2020 branded segment revenue by 65% and total company sales by 23%."
Endo International plc - Ordinary Shares closed on Wednesday at $85.65.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in